{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T16:57:04Z","timestamp":1780592224653,"version":"3.54.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2018,4,12]],"date-time":"2018-04-12T00:00:00Z","timestamp":1523491200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100006484","name":"AbbVie Deutschland","doi-asserted-by":"publisher","award":["German Synagis Registry"],"award-info":[{"award-number":["German Synagis Registry"]}],"id":[{"id":"10.13039\/100006484","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Pediatr"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1007\/s00431-018-3142-x","type":"journal-article","created":{"date-parts":[[2018,4,12]],"date-time":"2018-04-12T04:30:55Z","timestamp":1523507455000},"page":"903-911","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Palivizumab use in infants with Down syndrome\u2014report from the German Synagis\u2122 Registry 2009\u20132016"],"prefix":"10.1007","volume":"177","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9558-3330","authenticated-orcid":false,"given":"Arne","family":"Simon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Gehrmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gudrun","family":"Wagenpfeil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Wagenpfeil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,4,12]]},"reference":[{"issue":"4","key":"3142_CR1","doi-asserted-by":"publisher","first-page":"e1076","DOI":"10.1542\/peds.2007-0788","volume":"120","author":"BL Bloemers","year":"2007","unstructured":"Bloemers BL, van Furth AM, Weijerman ME, Gemke RJ, Broers CJ, van den Ende K, Kimpen JL, Strengers JL, Bont LJ (2007) Down syndrome: a novel risk factor for respiratory syncytial virus bronchiolitis\u2014a prospective birth-cohort study. Pediatrics 120(4):e1076\u2013e1081. \n                    https:\/\/doi.org\/10.1542\/peds.2007-0788","journal-title":"Pediatrics"},{"issue":"6","key":"3142_CR2","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1542\/peds.2010-1824","volume":"126","author":"NS Boghossian","year":"2010","unstructured":"Boghossian NS, Hansen NI, Bell EF, Stoll BJ, Murray JC, Laptook AR, Shankaran S, Walsh MC, Das A, Higgins RD (2010) Survival and morbidity outcomes for very low birth weight infants with Down syndrome. Pediatrics 126(6):1132\u20131140. \n                    https:\/\/doi.org\/10.1542\/peds.2010-1824","journal-title":"Pediatrics"},{"issue":"12","key":"3142_CR3","doi-asserted-by":"publisher","first-page":"e290","DOI":"10.1097\/INF.0000000000000922","volume":"34","author":"P Chan","year":"2015","unstructured":"Chan P, Li A, Paes B, Abraha H, Mitchell I, Lanctot KL (2015) Adherence to palivizumab for respiratory syncytial virus prevention in the Canadian Registry of Palivizumab. Pediatr Infect Dis J 34(12):e290\u2013e297. \n                    https:\/\/doi.org\/10.1097\/inf.0000000000000922","journal-title":"Pediatr Infect Dis J"},{"key":"3142_CR4","unstructured":"Deutsche Gesellschaft f\u00fcr P\u00e4diatrische Infektiologie (DGPI), Deutsche Gesellschaft f\u00fcr P\u00e4diatrische Kardiologie (DGPK), Deutsche Gesellschaft f\u00fcr P\u00e4diatrische Pneumonologie (DPP), Deutsche Gesellschaft f\u00fcr Neonatologie und P\u00e4diatrische Intensivmedizin (GNPI) (2008) Stellungnahme zur Prophylaxe von schweren RSV-Erkrankungen bei Risikokindern mit Palivizumab. http:\/\/wwwdgpide\/pdf\/Palivizumab_LL_final_30Sep2008pdf (30. September 2008)"},{"key":"3142_CR5","unstructured":"Deutsche Gesellschaft f\u00fcr P\u00e4diatrische Infektiologie (DGPI), Deutsche Gesellschaft f\u00fcr P\u00e4diatrische Kardiologie (DGPK), Gesellschaft f\u00fcr P\u00e4diatrische Pneumologie (GPP), Gesellschaft f\u00fcr Neonatologie und P\u00e4diatrische Intensivmedizin (GNPI), Berufsverband der Kinder- und Jugend\u00e4rzte (BVKJ), Bundesverband \u201eDas fr\u00fchgeborene Kind\u201c e.V. (2012) AWMF-LL 048-012 - Leitlinie zur Prophylaxe von schweren Erkrankungen durch Respiratory Syncytial Virus (RSV) bei Risikokindern 28. Oktober2012"},{"issue":"4","key":"3142_CR6","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1067\/S0022-3476(03)00454-2","volume":"143","author":"TF Feltes","year":"2003","unstructured":"Feltes TF, Cabalka AK, Meissner HC, Piazza FM, Carlin DA, Top FH Jr, Connor EM, Sondheimer HM (2003) Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr 143(4):532\u2013540","journal-title":"J Pediatr"},{"issue":"6","key":"3142_CR7","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1056\/NEJMoa0804877","volume":"360","author":"CB Hall","year":"2009","unstructured":"Hall CB, Weinberg GA, Iwane MK, Blumkin AK, Edwards KM, Staat MA, Auinger P, Griffin MR, Poehling KA, Erdman D, Grijalva CG, Zhu Y, Szilagyi P (2009) The burden of respiratory syncytial virus infection in young children. N Engl J Med 360(6):588\u2013598. \n                    https:\/\/doi.org\/10.1056\/NEJMoa0804877","journal-title":"N Engl J Med"},{"issue":"6","key":"3142_CR8","first-page":"943","volume":"26","author":"MS Kabbani","year":"2005","unstructured":"Kabbani MS, Giridhar S, Elbarbary M, Elgamal MA, Najm H, Godman M (2005) Postoperative cardiac intensive care outcome for Down syndrome children. Saudi Med J 26(6):943\u2013946","journal-title":"Saudi Med J"},{"issue":"6","key":"3142_CR9","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1093\/cid\/cir928","volume":"54","author":"K Kristensen","year":"2012","unstructured":"Kristensen K, Hjuler T, Ravn H, Simoes EA, Stensballe LG (2012) Chronic diseases, chromosomal abnormalities, and congenital malformations as risk factors for respiratory syncytial virus hospitalization: a population-based cohort study. Clin Infect Dis 54(6):810\u2013817. \n                    https:\/\/doi.org\/10.1093\/cid\/cir928","journal-title":"Clin Infect Dis"},{"issue":"10","key":"3142_CR10","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1136\/adc.2008.143057","volume":"94","author":"K Kristensen","year":"2009","unstructured":"Kristensen K, Stensballe LG, Bjerre J, Roth D, Fisker N, Kongstad T, Svendsen AL, Nielsen BW (2009) Risk factors for respiratory syncytial virus hospitalisation in children with heart disease. Arch Dis Child 94(10):785\u2013789. \n                    https:\/\/doi.org\/10.1136\/adc.2008.143057","journal-title":"Arch Dis Child"},{"issue":"1","key":"3142_CR11","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.anpedi.2008.11.007","volume":"71","author":"C Medrano Lopez","year":"2009","unstructured":"Medrano Lopez C, Garcia-Guereta Silva L, Lirio Casero J, Garcia Perez J (2009) Respiratory infections, Down\u2019s syndrome and congenital heart disease: the CIVIC 21 study. An Pediatr (Barc) 71(1):38\u201346. \n                    https:\/\/doi.org\/10.1016\/j.anpedi.2008.11.007","journal-title":"An Pediatr (Barc)"},{"issue":"7","key":"3142_CR12","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1097\/INF.0b013e3181d7ffa5","volume":"29","author":"O Megged","year":"2010","unstructured":"Megged O, Schlesinger Y (2010) Down syndrome and respiratory syncytial virus infection. Pediatr Infect Dis J 29(7):672\u2013673. \n                    https:\/\/doi.org\/10.1097\/INF.0b013e3181d7ffa5","journal-title":"Pediatr Infect Dis J"},{"issue":"Suppl 1","key":"3142_CR13","doi-asserted-by":"publisher","first-page":"S55","DOI":"10.1016\/j.earlhumdev.2011.01.012","volume":"87","author":"B Paes","year":"2011","unstructured":"Paes B, Manzoni P (2011) Special populations: do we need evidence from randomized controlled trials to support the need for respiratory syncytial virus prophylaxis? Early Hum Dev 87(Suppl 1):S55\u2013S58. \n                    https:\/\/doi.org\/10.1016\/j.earlhumdev.2011.01.012","journal-title":"Early Hum Dev"},{"key":"3142_CR14","doi-asserted-by":"publisher","unstructured":"PaesB, MitchellI, LiA, HarimotoT, LanctotKL (2013) Respiratory-related hospitalizations following prophylaxis in the Canadian registry for palivizumab (2005-2012) compared to other international registries. Clin Dev Immunol2013:917068. doi:\n                    https:\/\/doi.org\/10.1155\/2013\/917068\n                    \n                  , 1, 15","DOI":"10.1155\/2013\/917068"},{"key":"3142_CR15","doi-asserted-by":"crossref","unstructured":"Paes B, Mitchell I, Li A, Lanctot KL (2012) A comparative study of respiratory syncytial virus (RSV) prophylaxis in premature infants within the Canadian Registry of Palivizumab (CARESS). Eur J Clin Microbiol Infect Dis 31(10):2703\u20132711. https:\/\/doi.org\/10.1007\/s10096-012-1617-7 [doi]","DOI":"10.1007\/s10096-012-1617-7"},{"key":"3142_CR16","doi-asserted-by":"crossref","unstructured":"Paes B, Mitchell I, Li A, Lanctot KL (2012) Respiratory hospitalizations and respiratory syncytial virus prophylaxis in special populations. Eur J Pediatrin press. https:\/\/doi.org\/10.1007\/s00431-011-1654-8 [doi]","DOI":"10.1007\/s00431-011-1654-8"},{"key":"#cr-split#-3142_CR17.1","unstructured":"5. Paes B, Mitchell I, Li A, Lanctot KL (2012) Respiratory hospitalizations and respiratory syncytial virus prophylaxis in special populations. Eur J Pediatr 171"},{"key":"#cr-split#-3142_CR17.2","doi-asserted-by":"crossref","unstructured":"10.1007\/s00431-011-1654-8","DOI":"10.1007\/s00431-011-1654-8"},{"issue":"2","key":"3142_CR18","doi-asserted-by":"publisher","first-page":"e29","DOI":"10.1097\/INF.0000000000000019","volume":"33","author":"B Paes","year":"2014","unstructured":"Paes B, Mitchell I, Yi H, Li A, Lanctot KL (2014) Hospitalization for respiratory syncytial virus illness in Down syndrome following prophylaxis with palivizumab. Pediatr Infect Dis J 33(2):e29\u2013e33. \n                    https:\/\/doi.org\/10.1097\/inf.0000000000000019","journal-title":"Pediatr Infect Dis J"},{"key":"3142_CR19","doi-asserted-by":"crossref","unstructured":"Perez-Padilla R, Fernandez R, Garcia-Sancho C, Franco-Marina F, Aburto O, Lopez-Gatell H, Bojorquez I (2010) Pandemic (H1N1) 2009 virus and Down syndrome patients. Emerg Infect Dis 16(8):1312\u20131314. https:\/\/doi.org\/10.3201\/eid1608.091931 [doi]","DOI":"10.3201\/eid1608.091931"},{"key":"3142_CR20","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1111\/irv.12431","volume":"11","author":"M Sanchez-Luna","year":"2016","unstructured":"Sanchez-Luna M, Medrano C, Lirio J (2016) Down syndrome as risk factor for respiratory syncytial virus hospitalization: a prospective multicenter epidemiological study. Influenza Other Respir Viruses 11:157\u2013164. \n                    https:\/\/doi.org\/10.1111\/irv.12431","journal-title":"Influenza Other Respir Viruses"},{"key":"3142_CR21","doi-asserted-by":"crossref","unstructured":"Simon A, Nowak H, Sterz R (2011) Use of Palivizumab in Germany: data from 2002\u20132007. Klin Padiatr 223(5):292\u2013298. https:\/\/doi.org\/10.1055\/s-0030-1270515 [doi]","DOI":"10.1055\/s-0030-1270515"},{"issue":"6","key":"3142_CR22","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1097\/MPH.0b013e31806451c1","volume":"29","author":"A Simon","year":"2007","unstructured":"Simon A, Volz S, Fleischhack G, Tillman R, Muller A, Bode U, Schildgen O (2007) Human coronavirus OC43 pneumonia in a pediatric cancer patient with down syndrome and acute lymphoblastic leukemia. J Pediatr Hematol Oncol 29(6):432\u2013434","journal-title":"J Pediatr Hematol Oncol"},{"issue":"3","key":"3142_CR23","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1016\/j.jpeds.2014.11.058","volume":"166","author":"DR Stagliano","year":"2015","unstructured":"Stagliano DR, Nylund CM, Eide MB, Eberly MD (2015) Children with Down syndrome are high-risk for severe respiratory syncytial virus disease. J Pediatr 166(3):703\u2013709e702. \n                    https:\/\/doi.org\/10.1016\/j.jpeds.2014.11.058","journal-title":"J Pediatr"},{"issue":"Suppl 1","key":"3142_CR24","doi-asserted-by":"publisher","first-page":"A61.3","DOI":"10.1136\/archdischild-2014-306576.175","volume":"99","author":"C Sullivan","year":"2014","unstructured":"Sullivan C, Morgan C (2014) PC.74 The importance of testing for Respiratory Syncytial Virus (RSV) in infants presenting with bronchiolitis who are receiving palivizumab. Arch Dis Child Fetal Neonatal Ed 99(Suppl 1):A61.3\u2013A6A61. \n                    https:\/\/doi.org\/10.1136\/archdischild-2014-306576.175","journal-title":"Arch Dis Child Fetal Neonatal Ed"},{"issue":"3 Pt 1","key":"3142_CR25","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1542\/peds.102.3.531","volume":"102","author":"The IMpact-RSV Study Group","year":"1998","unstructured":"The IMpact-RSV Study Group (1998) Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 102(3 Pt 1):531\u2013537","journal-title":"Pediatrics"},{"key":"3142_CR26","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s40267-015-0275-0","volume":"32","author":"B Whelan","year":"2016","unstructured":"Whelan B, Musters E, Murray A, Moore E, Lievaart L, Visser S, Toxopeus E, van Veen A, Notario G, Campbell FJ (2016) Review of the home care programmes for respiratory syncytial virus (RSV) prophylaxis in Ireland and The Netherlands. Drugs Therapy Perspectives: Rational Drug Selection Use 32:119\u2013130. \n                    https:\/\/doi.org\/10.1007\/s40267-015-0275-0","journal-title":"Drugs Therapy Perspectives: Rational Drug Selection Use"},{"issue":"6","key":"3142_CR27","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1542\/peds.2013-3916","volume":"133","author":"H Yi","year":"2014","unstructured":"Yi H, Lanctot KL, Bont L, Bloemers BL, Weijerman M, Broers C, Li A, Kiss A, Mitchell I, Paes B (2014) Respiratory syncytial virus prophylaxis in Down syndrome: a prospective cohort study. Pediatrics 133(6):1031\u20131037. \n                    https:\/\/doi.org\/10.1542\/peds.2013-3916","journal-title":"Pediatrics"},{"key":"3142_CR28","doi-asserted-by":"crossref","unstructured":"Zachariah P, Ruttenber M, Simoes EA (2011) Hospitalization due to respiratory syncytial virus in children with congenital malformations. Pediatr Infect Dis J 30(5):442\u2013445. https:\/\/doi.org\/10.1097\/INF.0b013e318201813b [doi]","DOI":"10.1097\/INF.0b013e318201813b"},{"issue":"5","key":"3142_CR29","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1016\/j.jpeds.2011.11.004","volume":"160","author":"P Zachariah","year":"2012","unstructured":"Zachariah P, Ruttenber M, Simoes EA (2012) Down syndrome and hospitalizations due to respiratory syncytial virus: a population-based study. J Pediatr 160(5):827\u2013831. \n                    https:\/\/doi.org\/10.1016\/j.jpeds.2011.11.004","journal-title":"J Pediatr"}],"container-title":["European Journal of Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00431-018-3142-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00431-018-3142-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00431-018-3142-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,11]],"date-time":"2019-04-11T19:30:29Z","timestamp":1555011029000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00431-018-3142-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,12]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["3142"],"URL":"https:\/\/doi.org\/10.1007\/s00431-018-3142-x","relation":{},"ISSN":["0340-6199","1432-1076"],"issn-type":[{"value":"0340-6199","type":"print"},{"value":"1432-1076","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,12]]},"assertion":[{"value":"6 November 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 March 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"AbbVie Deutschland GmbH & Co KG, Wiesbaden, Germany provided financial support for this Registry. AbbVie participated in the review and approval of the manuscript. Susanne Gehrmann is Medical Unit Leader in the Medical Affairs Department of AbbVie Deutschland GmbH & Co.KG, Wiesbaden and may own AbbVie stock or stock options. Arne Simon has received scientific grants from Abbott GmbH, Wiesbaden for the DSM RSV Paed Study and honoraria for the development and scientific administration of Internet-based Version of the German Synagis\u2122 Registry from AbbVie Deutschland GmbH & Co.KG, Wiesbaden, Germany. Stefan Wagenpfeil has received scientific grants from AbbVie Deutschland GmbH & Co. KG for epidemiologic evaluation of the German Synagis\u2122 Registry. Gudrun Wagenpfeil has no conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Parents\/legal guardians provided written informed consent for data recording on the eCRF and anonymized data analysis and publication for scientific purposes. Before the practical implementation of the protected Internet data entry platform, the medical advisor of the study (AS) obtained approval for the POMS by the Ethics Committee of the Medical Faculty, University of Bonn, Germany (reference no. 132\/08). This approval was prolonged to July 2012 on September 9, 2010. After a change of affiliation to the University Hospital Homburg\/Saar, approval for the study was obtained by the Ethics Committee of the Medical Association of the Saarland on April 13, 2013 (reference no. Ha89\/13).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}